Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fidia FDA Orphan Drug Designation for ONCOFID®-P for Malignant Mesothelioma
Details : ONCOFID®-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.
Product Name : Oncofid-P
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
July 26, 2021
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable